<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105390</url>
  </required_header>
  <id_info>
    <org_study_id>E1B09</org_study_id>
    <secondary_id>NCI-2011-02068</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <secondary_id>CDR0000670445</secondary_id>
    <nct_id>NCT01105390</nct_id>
  </id_info>
  <brief_title>AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma</brief_title>
  <official_title>A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Patients With Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well giving AMG 102 together with pemetrexed disodium and&#xD;
      cisplatin works in treating patients with malignant pleural mesothelioma. Monoclonal&#xD;
      antibodies, such as AMG 102, can block tumor growth in different ways. Some block the ability&#xD;
      of tumor cells to grow or spread. Others find tumor cells and help kill them or carry&#xD;
      tumor-killing substances to them. Drugs used in chemotherapy, such as pemetrexed disodium and&#xD;
      cisplatin, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving AMG 102 together with pemetrexed disodium and&#xD;
      cisplatin may kill more tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the progression-free survival of patients with malignant pleural mesothelioma&#xD;
      (MPM) treated with anti-HGF monoclonal antibody AMG 102 in combination with pemetrexed&#xD;
      disodium and cisplatin.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the toxicity associated with this regimen in these patients. II. To determine&#xD;
      the response rate of patients treated with this regimen. III. To determine the overall&#xD;
      survival of patients treated with this regimen. IV. To evaluate multiple potential&#xD;
      correlative biomarkers in MPM that are relevant to this combined regimen, including serum HGF&#xD;
      and mesothelin levels, c-met expression by IHC in tumor specimens, presence of c-met&#xD;
      mutations in tumor, and the presence of thymidylate synthetase (TS) and excision repair cross&#xD;
      complementing protein-1 (ERCC1) polymorphisms.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed&#xD;
      disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every&#xD;
      21 days for 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3&#xD;
      weeks, as maintenance therapy in the absence of disease progression. Some patients undergo&#xD;
      blood sample collection at baseline and periodically during study for correlative biomarker&#xD;
      studies. Tumor samples from diagnostic tissue may also be analyzed.&#xD;
&#xD;
      After completion of study therapy, patients are followed up periodically every 3 months for 2&#xD;
      years and then every 6 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    withdrawn&#xD;
  </why_stopped>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From registration to clinical evidence of disease progression or death without progression, assessed up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity defined as a grade 4 hemorrhagic event or a grade 5 event</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Graded using the NCI CTCAE.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Advanced Malignant Mesothelioma</condition>
  <condition>Epithelial Mesothelioma</condition>
  <condition>Recurrent Malignant Mesothelioma</condition>
  <condition>Sarcomatous Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Treatment (rilotumumab, cisplatin, pemetrexed disodium)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3 weeks, as maintenance therapy in the absence of disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rilotumumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (rilotumumab, cisplatin, pemetrexed disodium)</arm_group_label>
    <other_name>AMG 102</other_name>
    <other_name>anti-HGF monoclonal antibody AMG 102</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (rilotumumab, cisplatin, pemetrexed disodium)</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (rilotumumab, cisplatin, pemetrexed disodium)</arm_group_label>
    <other_name>ALIMTA</other_name>
    <other_name>LY231514</other_name>
    <other_name>MTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (rilotumumab, cisplatin, pemetrexed disodium)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically and cytologically confirmed malignant mesothelioma of the pleura&#xD;
&#xD;
               -  All subtypes allowed&#xD;
&#xD;
               -  Disease not amenable to curative surgery&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Patients with disease not measurable by standard RECIST criteria (i.e., pleural&#xD;
                  rinds/thickening only) allowed&#xD;
&#xD;
               -  Pleural effusions or positive bone scans are not considered measurable&#xD;
&#xD;
          -  No prior radiotherapy to the target lesion or measurable lesion unless the site has&#xD;
             subsequent evidence of progression&#xD;
&#xD;
          -  Patients who have undergone pleurodesis allowed&#xD;
&#xD;
               -  Post-pleurodesis CT scan required&#xD;
&#xD;
          -  No known or suspected brain metastases&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 1.5 times ULN&#xD;
&#xD;
          -  ALT and AST ≤ 1.5 times ULN&#xD;
&#xD;
          -  Albumin ≥ 2.5 g/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 45 mL/min OR serum creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Able to take folic acid and vitamin B12&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must agree to use effective contraception&#xD;
&#xD;
          -  No active infection or serious concomitant systemic disorder in compatible with the&#xD;
             study&#xD;
&#xD;
          -  No thrombosis or vascular ischemic events within the last 12 months, including any of&#xD;
             the following:&#xD;
&#xD;
               -  Deep venous thrombosis&#xD;
&#xD;
               -  Pulmonary embolism&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
               -  Cerebral infarction&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
          -  No peripheral edema ≥ grade 3&#xD;
&#xD;
          -  No serious or non-healing wounds&#xD;
&#xD;
          -  No second primary malignancy except in situ carcinoma of the cervix or breast, other&#xD;
             in situ malignancies, adequately treated basal cell carcinoma of the skin, or other&#xD;
             malignancy within the past 3 years with no evidence of recurrence&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 30 days since major surgery procedures or &gt; 14 days since any minor surgical&#xD;
             procedure and recovered&#xD;
&#xD;
               -  Central venous catheter placement, fine-needle aspiration, thoracentesis, or&#xD;
                  paracentesis are not considered major or minor surgical procedures&#xD;
&#xD;
          -  No prior systemic chemotherapy for mesothelioma&#xD;
&#xD;
          -  No prior intracavity cytotoxic drugs or immunomodulators (unless for the purpose of&#xD;
             pleurodesis)&#xD;
&#xD;
          -  No prior anti-HGF monoclonal antibody AMG 102, other c-MET, or HGF inhibitors&#xD;
&#xD;
          -  No prior or concurrent anticoagulation therapy within the past 7 days&#xD;
&#xD;
               -  Low-dose Coumadin-type anticoagulants or low-molecular weight heparin for&#xD;
                  prophylaxis against central venous catheter thrombosis allowed&#xD;
&#xD;
          -  No investigational agents within the past 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Stevenson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Cooperative Oncology Group</affiliation>
  </overall_official>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Rilotumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

